Chylous ascites occurring after low anterior resection of the rectum successfully treated with an oral fat-free elemental diet (Elental®)

Gakuryu Nakayama · Daisuke Morioka · Takashi Murakami · Hideki Takakura · Yasuhiko Miura · Shinji Togo

Received: 11 February 2012 / Accepted: 6 April 2012 / Published online: 13 May 2012
© The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract Chylous ascites occurring after abdominal surgery is rare. Despite being potentially critical, there is no definite treatment guideline because of its rarity. Here we present a case of massive chylous ascites occurring after rectal surgery which was successfully treated with an oral fat-free elemental diet (ED). A 67-year-old man underwent low anterior resection with para-aortic lymphadenectomy for advanced rectal cancer. Early postoperative course was uneventful and the patient was discharged from hospital 10 days after surgery; however, after discharge, abdominal distension rapidly developed. Abdominal computed tomography (CT) performed 3 weeks after surgery revealed massive ascites and laboratory findings showed remarkable hypoproteinemia and lymphopenia. Urgent diagnostic paracentesis showed the ascites to be a white milky fluid containing high levels of triglycerides (564 mg/dl), leading to a diagnosis of chyloperitoneum. Daily nutrition of the patient was entirely with a fat-free ED (30 kcal/kg/day of Elental®, Ajinomoto Pharmaceutical Co. Ltd, Tokyo, Japan). After the initiation of oral Elental®, abdominal distension, hypoproteinemia, and lymphopenia gradually improved. Abdominal CT performed 7 weeks after surgery showed no ascitic fluid in the abdomen, and thereafter a normal diet was initiated. Since then, no relapse of chyloperitoneum has been proven. As a result, the chylous ascites was successfully treated in the outpatient clinic.

Keywords Chylous ascites · Colorectal surgery · Elemental diet

Abbreviations
TPN  Total parenteral nutrition
ED  Elemental diet
CT  Computed tomography

Introduction

Chylous ascites occurring after abdominal surgery is rare but has been reported in certain populations [1–4]. The reported incidence of this condition has varied because it is rare and sometimes asymptomatic [1–4]. If it becomes symptomatic, however, a massive loss of fat/protein-enriched fluid and lymphocytes can cause severe malnutrition and susceptibility to infection, leading to fatality [1–7]. Because of its rare occurrence, there is no consensus for management of this potentially lethal complication [1–7]. Therefore, reporting of new cases is useful for sharing valid experiences.

Sporadic case reports showed that total parenteral nutrition (TPN) with or without octreotide (or somatostatin) was effective for eradicating this condition [3–7]. However, TPN management requires hospitalization and a central venous catheter which is an invasive procedure [8]. Furthermore, treatment with octreotide and/or somatostatin requires close medical vigilance and high medical costs [8–11]. Here we present a case of massive chylous ascites occurring after rectal surgery which was successfully treated with an oral fat-free elemental diet (ED) in the outpatient clinic.

Case report

A 67-year-old man underwent low anterior resection with para-aortic lymphadenectomy for advanced rectal cancer. Neither neoadjuvant radiotherapy nor chemotherapy was...
performed. Early postoperative course was uneventful and the patient was discharged from hospital 10 days after the surgery. After discharge, however, abdominal distension developed and rapidly deteriorated. On the routine outpatient visit planned 21 days after surgery, the patient suffered from a severe sense of abdominal fullness and remarkable abdominal distension was noted with 92 cm of abdominal girth measured at the umbilicus. An emergency abdominal computed tomography (CT) scan proved that abdominal distension was caused by massive ascites (Fig. 1). Urgent diagnostic paracentesis showed that the ascites was a white milky fluid containing high levels of triglycerides (546 mg/dl), leading to a diagnosis of massive chylous ascites. Simultaneous laboratory findings showed severe hypoproteinemia (total protein 4.5 g/dl, albumin 2.1 g/dl) and lymphopenia (white cell count 3000/μl, lymphocyte count 150/μl). However, neither abdominal pain nor other signs suggestive of infection were found. Based on sporadic evidence that TPN with or without octreotide was reported to be effective for eradicating chyloperitoneum occurring after abdominal surgery [1–7], emergency admission was offered to the patient but rejected due to social reasons. Therefore, an oral fat-free ED (30 kcal/kg/day of Elental®, Ajinomoto Pharmaceutical Co. Ltd, Tokyo, Japan) was initiated. Elental® was given orally two or three times a day. Oral intake was strictly restricted to Elental®, water, and sugar/milk-free beverage. The patient was seen weekly in the outpatient clinic. After the initiation of oral Elental®, abdominal distension gradually improved. Most notably, the sense of abdominal fullness dramatically abated a few days after starting Elental®. His abdominal girth decreased to 82 cm and an abdominal CT scan showed no ascitic fluid in the abdomen 42 days after surgery. At that time, hypoproteinemia and lymphopenia improved (total protein 7.2 g/dl, albumin 4.2 g/dl, white cell count 6300/μl, lymphocyte count 2010/μl). Accordingly, the ED was totally replaced by a normal diet the following day, after which no abdominal distension was noted. As a result, the chylous ascites was successfully treated in the outpatient clinic. Six months after rectal surgery, the patient underwent partial hepatectomy (S8 segmentectomy) for liver metastasis originating from the rectal cancer. At that time, no ascitic fluid was seen in the abdomen. The patient is doing well without evidence of cancer recurrence or chyloperitoneum at 18 months after the initial rectal surgery (Fig. 2).
Discussion

Chylous ascites is caused by the unrecognized disruption of a major lymphatic channel during lymphadenectomy [1–7]. The most important issue regarding this rare but significant complication relates to prevention. Meticulous and systematic use of ligation or hemoclips before dividing distinguishable lymphatic vessels is essential for preventing this condition, notably in areas such as the para-aortic region where abdominal lymphatic systems converge and lymphatic fistula is apt to occur [1–7]. However, lymphatic vessels are often indistinguishable and thus chylous ascites cannot be completely prevented. Therefore, it is very important to establish a treatment strategy for this complication.

The choice of treatment for chylous ascites after abdominal surgery ranges from surgery to conservative treatment [1–7]. If the origin of the leak is definitely detected then surgical repair is preferred [12, 13]. However, imaging modalities for lymphatic structure in the abdomen require special instruments, materials, and expertise and are often unreliable [1–7, 12, 13]. Even if preoperative detection of the leakage site is available, the success rate of surgical repair for chylous ascites or abdominal lymphatic fistula has been reported to be low at approximately 50% because the anatomy of lymphatic systems in the abdomen is inconsistent unlike in the thorax [1–7]. As an initial treatment, therefore, surgical repair is considered to be impractical on many occasions.

As stated above, sporadic case reports showed that TPN with or without octreotide (or somatostatin) is promising for this complication [1–7]. However, these treatments require invasive procedures [8], close medical vigilance, and high medical costs [9–11]. In contrast, oral ED does not require specific instruments or procedures and is available in the outpatient clinic. Elental®, which was used in this case, is almost the same formula as VIVONEX® (Nestlé) which is available in many Western countries [14]. Elental® consists of 15% protein, 83.5% carbohydrate, and 1.5% fat (caloric distribution, % of kcal) and can provide nearly fat-free enteral nutrition [15], which does not need nutritional transport via mesenteric lymphatic systems and is therefore reasonable for mitigating chylous ascites [1–7]. Furthermore, Elental® is a completely digested formula and easily absorbed without digestive juice secretion, therefore, seldom causing bowel peristalsis which activates intra-abdominal lymphatic flow [14–16]. From this aspect, Elental® is considered superior to a conventional low-fat diet or medium-chain fat diet which requires digestive juice secretion for absorption and causes bowel peristalsis [1–5, 14–16]. Therefore, Elental® is considered markedly beneficial for decreasing intra-abdominal lymphatic flow and nutritionally promoting wound healing to repair disrupted lymph vessels. It was reported that conservative treatments for symptomatic postoperative chylous ascites required long-term (reportedly 40–90 days) management to achieve complete recovery [1–7]. In our case, this was achieved 28 days after initiating the Elental® diet. Furthermore, the patient was relieved from the severe sense of abdominal fullness shortly after starting the diet. These findings suggest that Elental® may be promising for treating postoperative chylous ascites. When prescribing an oral ED, low compliance was a problem because of its tastelessness [16]; however, various flavors have become available recently and compliance was reported to have increased [16]. If oral application is undurable, feeding via enteral tube is available and considered to be superior in intrinsic safety to TPN. Thus, fat-free ED can be recommended as an initial treatment for chylous ascites occurring after abdominal surgery because it is easy to start, intrinsically safe, and can be performed in the outpatient clinic if oral intake is available. Lacking strong evidence of its effectiveness, however, other treatment modalities such as TPN with or without octreotide must be initiated when ED is ineffective. Furthermore, surgical repair must always be considered; cases have been reported where conservative management did not cure chyloperitoneum and surgical repair was necessary [1–7]. Hence, it should be emphasized that meticulous, tactful, and appropriate management according to the individual case is essential for this rare but significant complication.

In conclusion, an oral fat-free ED can be recommended as an initial treatment for chylous ascites occurring after abdominal surgery because it is easy to start, intrinsically safe, and available in the outpatient clinic.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Aalami OO, Allen DB, Organ CH Jr. Chylous ascites: a collective review. Surgery. 2000;128:761–8.
2. Leibovitch I, Mor Y, Golomb J, Ramon J. The diagnosis and management of postoperative chylous ascites. J Urol. 2002;167:449–57.
3. Giovannini I, Giulianite F, Ciarla C, Ardito F, Vellone M, Nuzzo G. Non-surgical management of a lymphatic fistula, after laparoscopic colorectal surgery, with total parenteral nutrition, octreotide, and somatostatin. Nutrition. 2005;21:1065–7.
4. Nishigori H, Ito M, Nishizawa Y, Koyama A, Koda T, Nakajima K, Minagawa N, Nishizawa Y, Kobayashi A, Sugito M, Saito N.
Postoperative chylous ascites after colorectal cancer surgery. Surg Today. 2012 (Epub ahead of print).
5. Chen F-P, Lo T-S, Soong Y-K. Management of chylous ascites following laparoscopic presacral neurectomy. Hum Reprod. 1998;13:880–3.
6. Mincher L, Evans J, Jenner MW, Varney VA. The successful treatment of chylous effusions in malignant disease with octreotide. Clin Oncol. 2005;17:118–21.
7. Giovannini I, Giuliani F, Chiarla C, Giordano M, Ardito F, Vellone M, Sarno G, Nuzzo G. External lymphatic fistula after intra-abdominal lymphadenectomy for cancer. Treatment with total parenteral nutrition and somatostatin. Nutrition. 2008;24:1220–3.
8. Taylor RW, Palagiri AV. Central venous catheterization. Crit Care Med. 2007;35:1390–6.
9. Bonschein J, Drozdov I, Malfertheiner P. Octreotide LAR: safety and tolerability issues. Expert Opin Drug Saf. 2009;8:755–68.
10. Roehr CC, Jung A, Proquitte H, Blankenstein O, Hammer H, Lakhoo K, Wauer RR. Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review. Intensive Care Med. 2006;32:650–7.
11. Tolis G, Angelopoulos NG, Latounda E, Rombopolous G, Kaltzidou V, Kaltzas D, et al. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology. 2006;83:249–57.
12. Alejandre-Lafont E, Krompiec C, Rau WS, Krombach GA. Effectiveness of therapeutic lymphography on lymphatic leakage. Acta Radiol. 2011;52:305–11.
13. Kayano D, Taki J, Wakabayashi H, Kinuya S. Tc-99 m human serum albumin lymphoscintigraphy with SPECT/CT in chylothorax. Clin Nucl Med. 2011;36:1056–7.
14. Online Nestle Products Information. VIVONEX® T.E.N. http://www.nestle-nutrition.com/products/Product.aspx?ProductId=a3bc4b10-3701-4020-9742-d947a30ed612.
15. Pharmaceutical and Medical Devices Agency website. Elental. http://www.info.pmda.go.jp/go/pack/3259103B1036_2_01/.
16. Dray X, Marteau P. The use of enteral nutrition in the management of Crohn’s disease in adults. J Parenter Enteral Nutr. 2005;29(Suppl):S166–9.